Bionomics Limited (BNOEF) Research

Bionomics Limited, an Australian clinical-stage biopharmaceutical company founded in 1996 and based in Eastwood, focuses on identifying and developing innovative drug candidates to address central nervous system conditions and various cancers. A significant experimental medicine in their pipeline is BNC210, a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor. This compound is currently undergoing a Phase 2 clinical trial for social anxiety disorder and a Phase 2b study for post-traumatic stress disorder (PTSD). The company's portfolio also includes BNC101, a monoclonal antibody designed to combat cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Additionally, Bionomics is advancing BNC105, currently in a Phase 2 clinical trial for refractory colorectal cancer and a Phase 1 trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Market snapshot

Symbol
BNOEF
Price
$0.01
Day change
-14.89%
Market cap
$23.3M
P/E ratio
-0.85x
52-week range
0.0013-0.055
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Eiger BioPharmaceuticals, Inc. (EIGRQ)
  • The Flowr Corporation (FLWPF)
  • Forward Pharma A/S (FWPAY)
  • HealthBeacon plc (HBCNF)
  • Immune Therapeutics, Inc. (IMUN)
  • Living Cell Technologies Limited (LVCLY)
  • MDxHealth S.A. (MXDHF)
  • Polydex Pharmaceuticals Limited (POLXF)

Open Bionomics Limited (BNOEF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.